WO2006068662A1

WO2006068662A1 - Processes for the preparation of tomoxetine

Info

Publication number: WO2006068662A1
Application number: PCT/US2005/023412
Authority: WO
Inventors: Eugenio Castelli; Giuseppe Lo Monaco; Silvia Mantovani; Paola Daverio; Paolo Riva; Alessandra Vailati; Stefano Bianchi
Original assignee: Teva Pharmaceutical Fine Chemicals S.R.L.; Teva Pharmaceuticals Usa, Inc.
Priority date: 2004-06-28
Filing date: 2005-06-28
Publication date: 2006-06-29
Also published as: KR20070001250A; US7317127B2; US7507861B2; CA2561387A1; US20060009490A1; EP1761478B1; DK1761478T3; WO2006004923A3; WO2006004976A3; US20060009530A1; KR20070057703A; WO2006004977A3; ATE407111T1; CA2561015A1; US7355078B2; IL180357A0; US7378553B2; IL180355A0; EP1682485A2; IL180356A0

Abstract

Provided are processes for preparing tomoxetine comprising reacting Nmethyl-3-hydroxy-3-phenylpropylamine with dimethylsulfoxide (DMSO) and 2-fluorotoluene in the presence of an alkali base to form tomoxetine. Also provided is the conversion of said tomoxetine into atomoxetine or a pharmaceutically acceptable salt thereof.

Description

PROCESSES FOR THE PREPARATION OF TOMOXETINE

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefits of U.S. Provisional Patent Application Nos. 60/583,641, filed June 28, 2004, 60/609,716, filed September 14, 2004,

60/622,065, filed October 25, 2004, 60/652,330, filed February 11, 2005, 60/583,644, filed June 28, 2004, 60/652,332, filed February 11, 2005, 60/583,643, filed June 28, 2004, 60/652,331, filed February 11, 2005, 60/666,666, filed March 30, 2005, 60/675,369, filed April 26, 2005, Application No. Not Yet Known (Attorney Docket No. 12670/46803), filed June 9, 2005, and Application No. Not Yet Known (Attorney Docket No. 12670/47001), filed June 14, 2005, the contents of all of which are incorporated herein by reference.

FIELD OF THE INVENTION The present invention relates to new processes for preparing racemic tomoxetine.

BACKGROUND OF THE INVENTION

Atomoxetine, known as (R)(-)-N-methyl-3-(2-methylphenoxy)-3- phenylpropylamine, has the following structure:

Atomoxetine HCl (STRATTERA®) was originally developed as an antidepressant. It is currently marketed for the treatment of Attention-Deficit/

Hyperactivity Disorder (ADHD). Atomoxetine, the (R)-(-) enantiomer of tomoxetine, is an aryloxyphenylpropylamine (e.g., fluoxetine and nisoxetine). It is a competitive inhibitor of norepinephrine uptake in synaptosomes of rat hypothalamus and is approximately 2 and 9 times, respectively, more effective than the racemic mixture and the (+)-enantiomer. See for example: U.S. Pat. No. 4,018,895 (Eli Lilly and Co.), EP 0 052 492 (Eli Lilly and Co.), and EP 0 721 777 (Eli Lilly and Co.).

Several routes of synthesis for 3-aryloxy-3-phenylpropylamines are known in the art. For example, U.S. Pat. No. 4,018,895 by Eli Lilly and Co. discloses an aliphatic nucleophilic displacement of N-protected-3-halogen-3-phenylpropylamines by phenols, followed by N-deprotection. U.S. Pat. No. 4,868,344 by Aldrich-Boranes Inc. relates to the Mitsunobu reaction between 3-hydroxy-3-phenylpropylhalides and phenols, followed by amination of the resulting 3-aryloxy-3-phenylpropylhalides. Unfortunately, the synthetic routes disclosed in these patents require several steps and are burdened by the use of hazardous chemicals, such as diethylazadicarboxylate, triphenylphosphine and thionyl chloride.

U.S. Pat. No. 6,541,668, and WO 00/58262 by Eli Lilly and Co. as well as WO 94/00416 by Richter Gedeon Vegyeszeti Gyar RT disclose an aromatic nucleophilic displacement of an aryl halide by 3-hydroxy-3-phenylpropylamines under strongly basic conditions. The nucleophilic aromatic displacement process disclosed in WO 00/58262 involves reacting N-methyl-3-hydroxy-3- phenylpropylamine with a protected 2-fluorobenzaldehyde, which eventually leads, after functional group interconversion steps, to tomoxetine. The main drawbacks of this process are the additional steps required and the high cost of 2- fluorobenzaldehyde.

U.S. Pat. No. 6,541,668 discloses aromatic nucleophilic displacement conditions in the synthesis of tomoxetine: l,3-dimethyl-2-imidazolidinone or N- methylpyrrolidinone are used as solvents, starting from N-methyl-3-hydroxy-3- phenylpropylamine and 2-fluorotoluene, under strongly basic conditions (disclosed bases are alkali metal hydrides or alkoxides), at temperatures of less than about 140⁰C (yields data are not reported). As pointed out by the '668 patent, aromatic nucleophilic displacement giving tomoxetine cannot be carried out in conditions already known for other 3-aryloxy-3-phenylpropylamines, since 2-fluorotoluene is less activated than other aromatic rings used.

Tomoxetine is an intermediate in the preparation of atomoxetine HCl. A modest tomoxetine chemical yield with dimethylsulfoxide as a solvent was also reported in Koenig & Mitchell, Tetrahedron Letters, Vol. 35, n. 9, pp. 1339-1342 (1994). The base used is sodium hydride, a more reactive base than alkali metal hydroxides.

Other compounds, such as fluoxetine, can be synthesized through an aromatic nucleophilic displacement process, such as the one disclosed in WO 94/00416. As indicated by the disadvantages of the methods described in the related art, there is a need in the art therefore for additional processes for preparing tomoxetine in higher yields and shorter reaction times.

SUMMARY OF THE INVENTION The present invention provides a process for the preparation of tomoxetine utilizing N-methyl-3-hydroxy-3-phenylpropylamine as a starting material, which is reacted with dimethylsulfoxide (DMSO) and 2-fluorotoluene in the presence of an alkali base.

One aspect of the present invention is directed towards a process for the preparation of tomoxetine ((+) N-methyl-3-(2-methylρhenoxy)-3-phenylpropalamine) comprising the steps of:

(a) combining N-methyl-3-hydroxy-3-phenylpropylamine with dimethylsulfoxide in the presence of an alkali metal hydroxide to form a slurry; (b) adding 2-fluorotoluene to the slurry to obtain a reaction mixture;

(c) heating the resultant mixture to obtain tomoxetine; and

(d) recovering the formed tomoxetine .

Preferably, the resultant slurry in step (a) is heated prior to the addition of 2- fluorotoluene in step (b), to a temperature of at least 2O⁰C. More preferably, the slurry is heated to a temperature form about 80⁰C to about 110⁰C. hi a preferred embodiment, the resultant mixture in step (c) is heated to a temperature of about 8O⁰C to about 145°C. Preferably, when the amount of the alkali metal hydroxide added in step (a) is about 3 mole equivalents per mole equivalent of N-methyl-3-hydroxy-3-phenylpropylamine, the resultant mixture is heated to a temperature of about 135⁰C to about 145⁰C. Preferably, when the amount of the alkali metal hydroxide added in step (a) is about 5 mole equivalents per mole equivalent of N-methyl-3-hydroxy-3-phenylpropylamine, the resultant mixture is heated to a temperature of about 8O⁰C to 100⁰C. Another aspect of the present invention is directed to a process for preparing atomoxetine or a pharmaceutically acceptable salt thereof, comprising a step of preparing tomoxetine by the process described above.

Preferably, the pharmaceutically acceptable salt is atomoxetine hydrochloride

DETAILED DESCRIPTION OF THE INVENTION

As used herein, "room temperature" is meant to indicate a temperature of about 18-25°C, preferably about 20-22°C.

As used herein the term "aromatic solvent" refers to a C_6-10 aromatic hydrocarbon such as but not limited to benzene, xylene, or toluene.

The present invention provides a process for the preparation of tomoxetine that improves reaction yields and/or shortens the total reaction time. This process comprises the steps of:

(a) combining N-methyl-3-hydroxy-3-phenylpropylamine with dimethylsulfoxide (DMSO) in the presence of an alkali metal hydroxide to form a slurry;

(b) adding 2-fluorotoluene to the slurry to obtain a reaction mixture;

(c) heating the resultant mixture to obtain tomoxetine; and

(d) recovering the formed tomoxetine. DMSO is used as a reagent and not as a solvent, thus it may be added in small amounts, and may be even considered a catalyst. The amount of DMSO used in the reaction is about 0.1 to about 20 moles per mole of N-methyl-3-hydroxy-3- phenylpropylamine. Preferably, DMSO is added in an amount of about 3 moles to about 4 moles per mole of N-methyl-S-hydroxy-S-phenylpropylamine. Suitable alkali metal hydroxides may be selected from the group consisting of potassium hydroxide, barium hydroxide and sodium hydroxide. Preferably, the alkali metal hydroxide is potassium hydroxide.

The alkali metal hydroxide in this process is used instead of tert-butoxide, which is used by Eli Lilly in US Pat. No. 6,541,668, and is a much more flammable, air sensitive and expensive reagent. The process of the present invention also avoids the use of sodium hydride, a costly and reactive base that produces tomoxetine in low yields. See for example Koenig & Mitchell, Tetrahedron Letters, Vol. 35, n. 9, pp. 1339-1342 (1994).The Applicants have found that the use of a strong base instead of sodium hydride and tert-butoxide, unexpectedly results in markedly improved yields and preferably in shorter reaction times.

Preferably, the resultant slurry in step (a) is heated prior to the addition of 2- fluorotoluene to a temperature of at least 20⁰C. Preferably, the slurry is heated to a temperature form about 80⁰C to 110⁰C.

Preferably, 2-fluorotoluene is added to the slurry in an amount of at least about 2 molar equivalents per molar equivalent of N-methyl-3-hydroxy-3- phenylpropylamine.

Optionally, the slurry may be concentrated to remove water, prior to the addition of 2-fluorotoluene. The distillation is preferably conducted by vacuum distillation, at a pressure of less than about 100 mm Hg. hi a preferred embodiment, the resultant mixture in step (c) is heated to a temperature of about 80⁰C to about 145⁰C. Preferably, when the amount of the alkali metal hydroxide added in step (a) is about 3 mole equivalents per mole equivalent of N-methyl-3-hydroxy-3-phenylpropylamine, the resultant mixture is heated to a temperature from about 135°C to about 145°C. Preferably, when the amount of the alkali metal hydroxide added in step (a) is about 5 mole equivalents per mole equivalent of N-methyl-3-hydroxy-3-phenylpropylamine, the resultant mixture is heated to a temperature of about 8O⁰C to about 100⁰C. Recovering tomoxetine from the reaction mixture can be performed by adding water and an organic solvent to obtain a two-phase system, followed by extraction of tomoxetine with the organic solvent. Preferably, the organic solvent is selected from the group consisting of aliphatic and aromatic hydrocarbons, esters and ethers. More preferably, the organic solvent is selected from the group consisting of toluene, 2- fluorotoluene, benzene, xylenes, di-isopropyl ether, methyl-tert-butyl ether, ethyl acetate n-butylacetate, and isobutylacetate. The preferred organic solvent is toluene or 2-fluorotoluene.

Tomoxetine prepared by the processes of the present invention is obtained in high yield, and preferably, in less than about 4 hours. This process also avoids the use of toxic amidic solvents, such as l,3-dimethyl-2-imidazolidinone or N- methylpyrrolidinone as disclosed in U.S. Pat. No. 6,541,668.

The present invention further provides processes for preparing atomoxetine and/or a pharmaceutically acceptable salt thereof which include the processes for preparing tamoxetine described herein-above. A preferred pharmaceutically acceptable salt is atomoxetine hydrochloride.

Atomoxetine hydrochloride may be prepared first by an optical resolution of the obtained tomoxetine racemate to yield (R)-(-)-tomoxetine (S)-(+)-mandelate, then adding a base to a mixture of (R)-(-)-tomoxetine (S)-(+)-mandelate and an organic solvent, followed by adding HCl, to obtain atomoxetine HCl.

Moreover, the present invention provides a process for preparing a pharmaceutical composition comprising atomoxetine or a pharmaceutically acceptable salt thereof, which comprises bringing the obtained atomoxetine or a pharmaceutically acceptable salt thereof into contact with one or more pharmaceutically acceptable carriers or excipients.

Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the preparation of the composition and methods of use of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.

EXAMPLES

HPLC analysis

Instrument: HPLC Hewlett Packard VWD detector HPl 100.

Column: YMC ODS-AQ 250mm x 4.6mm (i.d.) cod. AQ-303 Mobile phase: NaH₂PO₄ 0.02M pH 3

Buffer: acetonitrile gradient

Flow: 1.5 ml/min

Temperature: 40°C

Wavelength: 215 nm

Example 1:

Preparation of tomoxetine

30 g (0.384 mol) of dimethylsulfoxide, 20 g (0.121 mol) of N-methyl-3- hydroxy-3-phenylpropylamine and 22.6 g (0.363 mol) of potassium hydroxide (bulk industrial grade, 90.1% assay) were mixed while stirred and heated at 100°C for one hour. The resulting slurry was allowed to cool to 80⁰C, and 40.0 g (0.363 mol) of 2- fluorotoluene was added. The mixture was heated to reflux (135°C-137°C) for three hours and allowed to cool to about 90⁰C. 120 ml of water and 120 ml of toluene were then added. The mixture was stirred for several minutes, and the phases were separated. The aqueous phase was extracted with 3x30 ml of toluene. The organic phases were collected and washed with 3x30 ml of water. Final organic phase weight: 206 g. Tomoxetine content: 14.28% by weight (HPLC assay). Yield: 95.2%.

Example 2:

Preparation of tomoxetine

110 g (1.41 mol) of dimethylsulfoxide, 20 g (0.121 mol) of N-methyl-3- hydroxy-3-phenylpropylamine, and 22.6 g (0.363 mol) of potassium hydroxide (bulk industrial grade, 90.1% assay) were mixed while stirred at 20-25⁰C for one hour. 40.Og (0.363 mol) of 2-fluorotoluene was then added to the resulting slurry. The mixture was then heated to reflux (142-145°C) for two hours and allowed to cool to about 80°C. 120 ml of water and 120 ml of toluene were added. The mixture was stirred for several minutes, and the phases were separated. The aqueous phase was extracted with 3x20 ml of toluene. The organic phases were collected and washed with 4x30 ml of water. Final organic phase weight: 206 g. Tomoxetine content: 13.25% by weight (HPLC assay). Yield: 88.4%.

Example 3 :

Preparation of tomoxetine 1100 g (14.1 mol) of dimethylsulfoxide, 200 g (1.21 mol) of N-methyl-3- hydroxy-3-phenylpropylamine, and 221 g (3.63 mol) of potassium hydroxide (bulk industrial grade, 92.1% assay) were heated while stirred at 110⁰C. The mixture was then concentrated by vacuum distillation until about 130 g of solvent was removed. The mixture was allowed to cool to 8O⁰C, and 400 g (3.63 mol) of 2-fluorotoluene was added. The mixture was heated to reflux (145-147°C) for one hour and allowed to cool to about 90⁰C. 1000 ml of water and 1000 ml of toluene were then added. The mixture was stirred for several minutes and the phases were separated. The aqueous phase was extracted with 2x200 ml of toluene. The organic phases were collected and washed with 3x200 ml of water. Final organic phase weight: 1700 g. Tomoxetine content: 16.83% by weight (HPLC assay). Yield: 92.7%.

Example 4: Preparation of tomoxetine

189 g (2.422 mol) of dimethylsulfoxide, 100 g (0.606 mol) of N-methyl-3- hydroxy-3-phenylpropylamine, and 188.6 g (3.028 mol) of potassium hydroxide (bulk industrial grade, 90.1% assay) were mixed while stirred and heated at 100°C for one hour. The resulting slurry was allowed to cool to 80⁰C₅ and 200 g (1.816 mol) of 2- fluorotoluene was added. The mixture was heated to 95-100°C for three hours and allowed to cool to about 90⁰C. Then 400 ml of water and 250 ml of toluene were added. The mixture was stirred for several minutes, and the phases were separated. The aqueous phase was extracted with 2x50 ml of toluene. The organic phases were collected and washed with 2x50 ml of water. Final organic phase weight: 545 g. Tomoxetine content: 26.7% by weight (HPLC assay). Yield: 94%.

Example 5:

Preparation of tomoxetine

191 g (2.448 mol) of dimethylsulfoxide, 100 g (0.606 mol) of N-methyl-3- hydroxy-3-phenylpropylamine, and 188.6 g (3.024 mol) of potassium hydroxide (bulk industrial grade, 89.9% assay) were mixed while stirred and heated at 100°C-105°C for one hour. The resulting slurry was allowed to cool to 80°C-85°C, and 200 g (1.816 mol) of 2-fluorotoluene was added in one hour while the slurry was kept heated at

8O°C-85°C. The mixture was kept at 80°C-85°C for five hours, and 400 ml of water was added. The mixture was then stirred for several minutes, and the phases were separated. The organic phase was concentrated at reduced pressure to recover the unreacted 2-fluorotoluene. The aqueous phase was extracted with 100 ml of toluene.

The organic phases were collected. Final organic phase weight: 258.5 g. Tomoxetine content: 56.6 % by weight (HPLC assay). Yield: 95%.

Example 6:

Tomoxetine Optical Resolution

A solution in toluene of crude racemic tomoxetine (276.13 g, 1.081 mol, by

HPLC assay) prepared as described in example 1 was concentration in vacuum to remove water. The residue was taken up with 2025 ml of toluene and 26 ml of methanol. To the obtained solution 94 g (0.618 mol) of (S)-(+)-mandelic acid were added at 25°C. All solids were solubilized by heating to 65°-70°C. The crude mandelate salt was crystallized on cooling. The solid was isolated by filtration at 5°- 1O⁰C, washed with about 300 ml of toluene and dried in vacuo. Weight: 178 g. Tomoxetine content: 63.2% by weight (HPLC assay). Yield: 43.15%.Crude mandelate salt (R)-(-)-Tomoxetine enantiomeric ratio: R/S is about 95/5 (by chiral HPLC).

163 g of the obtained crude mandelate salt were re-crystallized from 489 ml of toluene and 49 ml of methanol as follows: the salt was solubilized by heating to 65°- 70°C, then (R)-(-)-tomoxetine (S)-(+)-mandelate was crystallized on cooling, isolated by filtration at 5°-10°C, washed with about 2 x 90 ml of toluene and dried in vacuum. Weight: 153 g. Tomoxetine content: 63.97% by weight (HPLC assay). Yield: 38.7% from racemic tomoxetine. (R)-(-)-tomoxetine (atomoxetine) enantiomeric ratio: R/S > 99/1 (by chiral HPLC).

Example 7:

Preparation of atomoxetine HCl

45 g (0.110 mol) of (R)-(-)-tomoxetine (S)-(+)-mandelate were mixed under stirring with 225 ml of toluene and 225 ml of water. Keeping the temperature at about 40°C by means of gentle heating, 21 g (about 0.16 mol) of 30% aqueous sodium hydroxide were added. The phases were then separated. The organic phase was washed with 100 ml of 1% aqueous sodium hydroxide, then filtered on paper and concentrated in vacuum to give 29.67 g of an oil containing 26.8 g of tomoxetine (by HPLC assay).

23.5 g of the oil were dissolved in 211 ml of ethyl acetate under stirring then, keeping temperature between 12°C and 18°C by means of water-ice bath cooling; gaseous hydrogen chloride was bubbled into the solution until acid reaction of litmus paper. The hydrochloride then crystallized. The obtained suspension was stirred at about 15°C for one hour, then the solid was collected by filtration, washed with ethyl acetate and dried in vacuo. Tomoxetine hydrochloride content: > 99% by HPLC assay. Weight: 24.3 (0.0832mol) g. Yield: 95%. Atomoxetine hydrochloride enantiomeric ratio: R/S > 99/1 (by chiral HPLC).

Claims

WHAT IS CLAIMED IS:

1. A process for the preparation of tomoxetine comprising:

(b) adding 2-fluorotoluene to the slurry to obtain a reaction mixture;

(c) heating the resultant mixture to obtain tomoxetine; and

(d) recovering the formed tomoxetine as a racemic mixture.

2. The process of claim 1 wherein the amount of DMSO combined in step (a) is about 0.1 to about 20 mole equivalents per mole N-methyl-3-hydroxy-3- phenylpropylamine.

3. The process of claim 2 wherein the amount of DMSO combined in step (a) is about 3 to about 4 mole equivalents per mole N-methyl-3-hydroxy-3- phenylpropylamine.

4. The process of claim 1 wherein the alkali metal hydroxide is selected firom the group consisting of potassium hydroxide, barium hydroxide, and sodium hydroxide.

5. The process of claim 4 where the alkali metal hydroxide is potassium hydroxide.

6. The process of claim 1 wherein the slurry in step (a) is heated, prior to the addition of 2-fluorotoluene in step (b), to a temperature of at least about 20⁰C.

7. The process of claim 6 wherein said slurry is heated to a temperature of about 80⁰C to about 100⁰C.

8. The process of claim 1 wherein the amount of the added 2-fluorotoluene is at least about 2 molar equivalents per molar equivalent of N-methyl-3-hydroxy-3- phenylpropylamine.

9. The process of claim 1 further comprises concentrating the slurry of step (a) prior to step (b).

10. The process of claims 1 wherein the alkali metal hydroxide is combined in step (a) in an amount of about 3 to about 5 molar equivalents per molar equivalent of the

N-methyl-3-hydroxy-3-phenylpropylamine.

11. The process of claim 1 wherein the mixture in step (c) is heated to a temperature from about 8O⁰C to about 145⁰C.

12. The process of claim 10 wherein 3 molar equivalents of said alkali metal hydroxide are used, and the mixture in step (c) is heated to a temperature of about 135⁰C to about 145°C.

13. The process of claim 10 wherein 5 molar equivalents of said alkali metal hydroxide are used, and the mixture in step (c) is heated to a temperature of about 80⁰C to about 100⁰C.

14. The process of claim 1 where the recovered tomoxetine is used for the production of atomoxetine or a pharmaceutically acceptable salt thereof.

15. A process for the preparation of atomoxetine or a pharmaceutically acceptable salt thereof comprising:

(a) combining N-methyl-3-hydroxy-3-phenylpropylamine with DMSO in the presence of an alkali metal hydroxide to form a slurry;

(b) adding 2-fluorotoluene to the slurry to obtain a reaction mixture;

(c) heating the resultant mixture to obtain tomoxetine;

(d) recovering the formed tomoxetine as a racemic mixture; and

(e) converting the tomoxetine recovered in step (d) to atomoxetine or a pharmaceutically acceptable salt thereof.

16. The process of claim 15, where the pharmaceutically acceptable salt is hydrochloride.

17. Use of the tomoxetine prepared according to any one of claims 1 to 14 in the preparation of atomoxetine.

18. Use of the tomoxetine prepared according to any one of claims 1 to 14 in the 5 preparation of atomoxetine HCl.

19. Use of the tomoxetine prepared according to any one of claims 1 to 14 in the preparation of pharmaceutical compositions comprising atomoxetine HCl.

10 20. A process for preparing a pharmaceutical composition comprising atomoxetine or a pharmaceutically acceptable salt thereof, which comprises bringing atomoxetine or a pharmaceutically acceptable salt thereof prepared according to claim 15 into contact with one or more pharmaceutically acceptable carriers or excipients.